Enoxaparin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Enoxaparin
- Pharmacist Assessment Report
- Enoxaparin: Thrombophilia due to protein C deficiency, autosomal recessive
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Enoxaparin: Thrombophilia due to protein C deficiency, autosomal recessive
One-Sentence Summary
Enoxaparin is a low-molecular-weight heparin (LMWH) anticoagulant, originally associated with pulmonary embolism, disseminated intravascular coagulation and purpura fulminans. The TxGNN model predicts it may be effective for thrombophilia due to protein C deficiency (autosomal recessive), but there are currently no registered clinical trials and no relevant publications supporting this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Thrombophilia due to protein C deficiency, autosomal recessive |
| TxGNN Prediction Score | 0.9958 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, enoxaparin is a low-molecular-weight heparin that potentiates antithrombin and inhibits factor Xa. This is plausible for managing thrombosis risk in protein C deficiency.
This supports the connection between the original and predicted indications.
However, standard care for severe congenital protein C deficiency relies on protein C concentrate and anticoagulation. Any role for enoxaparin would need dedicated clinical review. The support at present is a model prediction only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top predicted indication.
For context, the second- to tenth-ranked predictions were also reviewed. Literature was found only for three of them, and none of it directly evaluates enoxaparin as a treatment:
- Standard TTP therapy is plasma exchange, immunosuppression and caplacizumab.
- Anticoagulation is biologically plausible here, but the evidence is indirect.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13688K | Exarane Forte | Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Not provided |
Safety Considerations
The data compiled for this report did not include label-based warnings or contraindications. Please refer to the TGA-approved Product Information (PI) for these.
Contraindication-related conditions (from the knowledge graph, not label text): liver failure, thrombocytopenia (including heparin-induced thrombocytopenia), haemophilia and other blood coagulation diseases, qualitative platelet defects (including Glanzmann thrombasthenia), antithrombin III deficiency, intracranial and intracerebral haemorrhage, placental abruption, active peptic ulcer disease, ulcerative colitis and inflammatory bowel disease, infective endocarditis, biliary tract disease and obstructive jaundice, osteoporosis, and retinal disease (including diabetic and hypertensive retinopathy).
Drug Interactions: 100 interactions were identified, and the first 20 are summarised here.
- Major: acetylsalicylic acid, ibuprofen, ketorolac, abciximab, alteplase, acalabrutinib, deferasirox, trastuzumab emtansine, ibritumomab tiuxetan, tositumomab (including I-131 tositumomab).
- Moderate: fenfluramine, dexfenfluramine, sibutramine, aliskiren, sugammadex, iodide I-123 and I-131, topical diclofenac, ophthalmic ketorolac.
Several of the other top predicted indications are bleeding disorders or haemorrhage-prone conditions, where anticoagulation could worsen bleeding.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model score alone (Evidence Level L5), with no clinical trials or publications supporting enoxaparin in protein C deficiency. The mechanistic link is plausible, but established therapy (protein C concentrate and anticoagulation) already exists.
To proceed, the following is needed:
- A systematic literature review of LMWH use in congenital protein C deficiency and purpura fulminans
- Mechanism of action data, and the label-based warnings and contraindications from the TGA Product Information
- The approved indication text for the ARTG entry
- Expert haematology review of whether enoxaparin has any role alongside protein C replacement
- A bleeding-risk assessment given the contraindication profile
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.